Methods
Serum atomoxetine concentrations and CYP2D6/2C19 genotypes were included from a therapeutic drug monitoring service. Patients were first subgrouped according to CYP2D6 encoding normal, reduced or absent CYP2D6 metabolism, referred to as normal (NM), intermediate (IM) or poor metabolizers (PM). Then, the effect of reduced-function CYP2C19genotypes was investigated. Genotyping of the CYP2D6 nonfuctional or reduced variant alleles comprised CYP2D6*3 -*5 ,*9 -*10 and *41 . For CYP2C19, the CYP2C19*2was analysed to define metabolizer phenotype. Dose-adjusted serum atomoxetine concentration was the exposure measure.